Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187246 | 1.00 | CA2 (0.49) | CA2ACELMNAL3MBTL1NPC1 | |
| SCHEMBL18228991 | 0.87 | MEN1 (0.60) | CA2ACELMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL28672517 | 0.87 | MEN1 (0.60) | CA2ACELMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL18229063 | 0.84 | CTSL (0.51) | CA2ACEL3MBTL1ALDH1A1MME | |
| SCHEMBL18229005 | 0.84 | CA2 (0.49) | CA2ACELMNAL3MBTL1NPC1 | |
| SCHEMBL18229007 | 0.84 | ACE (0.52) | CA2ACEALDH1A1GPR34MME | |
| SCHEMBL20187245 | 0.84 | ACE (0.52) | CA2ACEALDH1A1GPR34MME | |
| SCHEMBL31006615 | 0.83 | CA2 (0.52) | CA2ACELMNANPC1RAB9A | |
| SCHEMBL20187248 | 0.82 | CTSL (0.51) | CA2ACEL3MBTL1MMECPA1 | |
| SCHEMBL18229001 | 0.82 | CTSL (0.51) | CA2ACEL3MBTL1MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107810189-B | Process for the preparation of nitrogen mustard derivatives | 肿瘤多肽股份公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3280721-B1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | ONCOPEPTIDES AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
| EP-3280721-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | Oncopeptides AB (SE) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016180740-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | CA2 300/4885ACE 1077/4885LMNA 2888/4885 |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | CBR3, GRHPR, CTH | CA2 300/4885ACE 1077/4885LMNA 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.